Endospan's NEXUS Aortic Arch Stent Graft Study Reaches Milestone
Endospan Completes Enrollment of Primary Arm in TRIOMPHE Study
Endospan, a leader in endovascular solutions for aortic arch disease, has proudly announced the completion of patient enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study targeting the NEXUS® Aortic Arch Stent Graft. This study is critical in assessing the safety and effectiveness of the device in treating patients with aortic arch disease.
About the NEXUS Aortic Arch Stent Graft
The NEXUS Aortic Arch Stent Graft is an advanced bi-modular off-the-shelf device that offers a minimally invasive solution specifically designed for individuals suffering from aortic arch disease. The TRIOMPHE IDE study is a non-randomized, three-arm investigation being conducted at 30 leading aortic centers in the United States, alongside one participating center in New Zealand. This study encompasses a diverse range of aortic arch pathologies, allowing for a comprehensive understanding of the device's performance.
Comments from Key Stakeholders
Kevin Mayberry, CEO of Endospan, expressed his excitement regarding the enrollment achievement: "We are thrilled to announce the completion of enrollment for the primary arm of this significant clinical study. The NEXUS Aortic Arch Stent Graft holds the promise of greatly enhancing patient outcomes in aortic arch disease cases. Our commitment lies in expediting the availability of this innovative technology—already recognized for its effectiveness in Europe—to the U.S. market as soon as possible."
Additionally, Dr. Brad Leshnower from Emory, who serves as the Cardiac National Principal Investigator for the study, shared his perspective: "We are enthusiastic to be implicated in this groundbreaking research. Preliminary results from the TRIOMPHE study, presented at a major conference this year, suggest that the NEXUS system is safely applicable for treating aortic arch disease in high-risk surgical groups with a lower likelihood of stroke. We look forward to the complete results from the entire patient cohort."
Revolutionizing Aortic Arch Treatment
Dr. Ross Milner from UChicago, the Vascular National Principal Investigator, remarked on the transformative potential of the NEXUS device: "This device could revolutionize how we approach treatments for aortic arch disease, providing a less invasive option compared to traditional open surgery. We are very eager to see how this study reveals the midterm durability and overall outcomes for patients."
The company is dedicated to monitoring the safety and effectiveness of patients for a year before submitting their data for FDA approval, reinforcing their commitment to setting high standards of care in this field.
About Endospan
Endospan is a privately held company with its operations headquartered in Herzlia, Israel. This pioneering organization specializes in the endovascular repair of aortic arch conditions, including aneurysms and dissections. The NEXUS® Aortic Arch Stent Graft System stands out as the first endovascular off-the-shelf system that has received a CE Mark, aimed at serving a significantly underserved population diagnosed with issues in or near the aortic arch.
While standard endovascular repairs for Abdominal Aortic Aneurysms (AAA) continue to advance, patients suffering from aortic arch diseases have faced limited options, often resorting to highly invasive open-chest surgeries associated with risks, extended hospital stays, and lengthy recovery times. The NEXUS system represents a beacon of hope for these patients.
Frequently Asked Questions
What is the TRIOMPHE IDE clinical study?
The TRIOMPHE IDE clinical study evaluates the safety and efficacy of the NEXUS Aortic Arch Stent Graft in treating aortic arch disease.
Where is the TRIOMPHE study being conducted?
The study is being conducted at 30 leading aortic centers across the United States and one center in New Zealand.
What is the significance of the NEXUS Aortic Arch Stent Graft?
The NEXUS Aortic Arch Stent Graft is designed to provide a minimally invasive treatment option for patients suffering from aortic arch disease.
What are the next steps for Endospan after enrollment completion?
Endospan plans to monitor patients for one year before submitting their findings for FDA approval.
What differentiates the NEXUS system from traditional treatments?
The NEXUS system offers a less invasive alternative to open surgery, potentially reducing risks and improving recovery times for patients.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study
- Nicholas Wealth Hits Milestone with $100 Million in FIAX ETF
- Acacia Research Strengthens Portfolio with Deflecto Acquisition
- SolarEdge Hits Milestone with Early Certification on Cybersecurity
- REGENXBIO Unveils Promising Insights from Phase II Wet AMD Study
- Canoo Achieves Key Regulatory Milestone for Electric Vans
- Endeavour Silver's Terronera Project Achieves Major Milestones
- EPC Group Triumphs with Milestones in SharePoint and AI Solutions
- Join RaySearch’s Q3 2024 Report Presentation and Insights
- Exploring Growth Opportunities with Lam Research and LRCX
Recent Articles
- Grab Holdings Preparing to Share Q3 2024 Financial Results
- SunHydrogen Advances Green Hydrogen Technologies in Pilot Phase
- Anaergia's Innovative Organic Waste Infrastructure in Riverside
- Highwoods Properties Announces Attractive Dividend Payments
- Latest Insights on Tutor Perini Corporation's Financial Progress
- Atlantic Union Bankshares Partners with Sandy Spring Bancorp
- Orbbec Launches Innovative Gemini 335Lg 3D Camera at ROSCon 2024
- Atlantic Union Bankshares Corporation Prices Stock Offering
- FII8 Conference: Unlocking Global Opportunities for Innovation
- Investcorp AI Acquisition Corp. to Merge with Bigtincan Holdings
- Great American Media Unveils New Faith Film 'God's Not Dead'
- Understanding Acadia Healthcare's Legal Challenges and Investors' Rights
- Exciting Offers for MyPanera Week at Panera Bread
- Titan International Secures Capital with Share Buyback Strategy
- Edwards Lifesciences Investors: Class Action Opportunity Ahead
- Cigna Healthcare's Commitment to Combat Senior Food Insecurity
- Rönesans Holding Secures Investment for Landmark Motorway Project
- Revolutionizing Mainframe Development with AI and Community Efforts
- Innovative Approach in Liver Transplants with HOPE Technology
- ComplyControl Unveils Innovative Brand Overhaul to Support Growth
- Construction Partners to Acquire Lone Star Paving for $654M
- Leonard A. Lauder Recognized with Neiman Marcus Fashion Award
- Realta Wealth Welcomes Abbey Eastham as Key Executive Leader
- Leonard A. Lauder's Remarkable Legacy Recognized
- JinkoSolar's Jiangxi Subsidiary Plans Major Share Offering
- Rising Demand for Black Mass Recycling Forecast to Reach $51.70B
- Rönesans Holding Champions Sustainability in Infrastructure Projects
- Leveraging HOPE: Transforming Liver Transplantation Practices
- Construction Partners, Inc. Prepares for Fiscal 2025 Growth
- Centerspace Faces Challenges as Rent Growth Slows in Key Areas
- Bending Spoons Eyes Future IPO with Focus on US Market
- Market Prepares for Earnings Reports; Boeing Leads Gains
- UBS Takes Strategic Steps by Selling Swisscard Stake
- Microsoft Launches New Autonomous AI Agents for Customers
- Glunz & Jensen Reports Improved Q3 2024 Financial Results
- Elon Musk's PAC Giveaway Sparks Debate with Mark Cuban
- ByteDance Reacts to Intern Incident Impacting AI Development
- Sandvik Reports Mixed Performance for Q3 Financials
- Raymond James Upgrades Mid-America Apartment Communities Amid Growth
- Naqdi Expands Influence Through Strategic Sponsorship in Metro
- Essex Property Trust Faces Downgrade Amid Market Conditions
- JPMorgan Raises Price Target for Tech Mahindra Amid Caution
- HSBC Adjusts Target for ICICI Lombard, Maintains Buy Rating
- PBOC Executes Groundbreaking Swap Operation of 50 Billion Yuan
- CITIC Announces $430.3 Million Sale of Stake in McDonald's Operations
- Microsoft to Launch New Autonomous AI Agent Development Tools
- UPS Faces Downgrade Concerns Amid Margin Pressures from Rivals
- Strategists Recommend Investing in China and Equities
- Exciting MEXC and Aptos Partnership Unveils Major Prize Events
- Is Now the Time to Invest in Ally Financial Shares?